IP Library Granted Patent US 11,298,320
Granted Patent B2
US 11,298,320 · App. 17/330,209 · Granted Apr 12, 2022

Liposomal apparatus and manufacturing methods

Inventors: Ian MacLachlan (Vancouver, CA); Lloyd B. Jeffs (Vancouver, CA); Lorne R. Palmer (Vancouver, CA); Cory Giesbrecht (Vancouver, CA)
Assignee: ARBUTUS BIOPHARMA CORPORATION
A61K9/1271A61K9/127A61K9/1277A61K31/7084A61K31/7088A61K47/10A61K47/24A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,298,320
App. No.
17/330,209
Granted
Apr 12, 2022
Kind
B2
Abstract

The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.

Claims (38)

1. An apparatus for producing a lipid vesicle encapsulating a nucleic acid within the lipid vesicle, the apparatus comprising:

a first reservoir containing an aqueous solution including a nucleic acid;

a second reservoir containing an organic lipid solution, wherein the lipids present in the organic lipid solution are solubilized in a lower alkanol at a concentration of about 75% v/v to 100% v/v; and

a pump mechanism configured to pump the aqueous solution and the organic lipid solution into a mixing chamber at different flow rates relative to each other;

wherein the mixing chamber is configured such that the aqueous solution and the organic lipid solution are introduced into the mixing chamber as opposing flows at about 180° relative to each other and mixed within the mixing chamber to instantaneously produce a lipid vesicle encapsulating the nucleic acid within the lipid vesicle by diluting the concentration of the lower alkanol in the organic lipid solution.

2. The apparatus of claim 1 , wherein the lipids present in the organic lipid solution comprise a phospholipid, cholesterol, a PEG-lipid, and a cationic lipid.

3. The apparatus of claim 2 , wherein a plurality of lipid vesicles are produced and said plurality of lipid vesicles have a mean particle diameter of less than 150 nm.

4. The apparatus of claim 2 , wherein the aqueous solution includes an acidic buffer.

5. The apparatus of claim 2 , wherein the aqueous solution includes a buffer having a pH lower than the pKa of the cationic lipid component.

6. The apparatus of claim 2 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 6.

7. The apparatus of claim 2 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 8.

8. The apparatus of claim 1 , wherein the nucleic acid comprises an RNA.

9. The apparatus of claim 8 , wherein the lower alkanol comprises ethanol and wherein the lipids present in the organic lipid solution comprise a phospholipid, cholesterol, a PEG-lipid, and a cationic lipid.

10. The apparatus of claim 9 , wherein the aqueous solution includes an acidic buffer.

11. The apparatus of claim 9 , wherein the aqueous solution includes a buffer having a pH lower than the pKa of the cationic lipid component.

12. The apparatus of claim 9 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 6 and said plurality of lipid vesicles have a mean particle diameter of less than 150 nm.

13. The apparatus of claim 8 , wherein the RNA comprises an mRNA.

14. The apparatus of claim 13 , wherein the lower alkanol comprises ethanol and wherein the lipids present in the organic lipid solution comprise a phospholipid, cholesterol, a PEG-lipid, and a cationic lipid.

15. The apparatus of claim 14 , wherein the aqueous solution includes an acidic buffer.

16. The apparatus of claim 14 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 6 and said plurality of lipid vesicles have a mean particle diameter of less than 150 nm.

17. The apparatus of claim 14 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 8.

18. An apparatus for producing a lipid vesicle encapsulating a nucleic add within the lipid vesicle, the apparatus comprising:

a first reservoir containing an aqueous solution including a nucleic acid;

a second reservoir containing an organic lipid solution, wherein the lipids present in the organic lipid solution are solubilized in a lower alkanol at a concentration of about 75% v/v to 100% v/v; and

a pump mechanism configured to pump the aqueous solution and the organic lipid solution into a mixing chamber at different flow rates relative to each other;

wherein the mixing chamber is configured such that the aqueous solution and the organic lipid solution are introduced into the mixing chamber at an angle of between 90° and 180° relative to each other and mixed within the mixing chamber to instantaneously produce a lipid vesicle encapsulating the nucleic acid within the lipid vesicle by diluting the concentration of the lower alkanol in the organic lipid solution.

19. The apparatus of claim 18 , wherein the lower alkanol comprises ethanol and wherein the lipids present in the organic lipid solution comprise a phospholipid, cholesterol, a PEG-lipid, and a cationic lipid.

20. The apparatus of claim 19 , wherein the aqueous solution includes an acidic buffer having a pH lower than the pKa of the cationic lipid component.

21. The apparatus of claim 20 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 6 and said plurality of lipid vesicles have a mean particle diameter of less than 150 nm.

22. The apparatus of claim 20 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 8.

23. The apparatus of claim 18 , wherein the nucleic acid comprises an RNA.

24. The apparatus of claim 23 , wherein the lipids present in the organic lipid solution comprise a phospholipid, cholesterol, a PEG-lipid, and a cationic lipid.

25. The apparatus of claim 24 , wherein the aqueous solution includes an acidic buffer.

26. The apparatus of claim 24 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 8.

27. The apparatus of claim 23 , wherein the RNA comprises an mRNA.

28. The apparatus of claim 27 , wherein the lipids present in the organic lipid solution comprise a phospholipid, cholesterol, a PEG-lipid, and a cationic lipid.

29. The apparatus of claim 28 , wherein the aqueous solution includes a buffer having a pH lower than the pKa of the cationic lipid component.

30. The apparatus of claim 28 , wherein the aqueous solution and the organic lipid solution are mixed within the mixing chamber to produce a plurality of lipid vesicles at a pH range of about 3.5 to about 6 and said plurality of lipid vesicles have a mean particle diameter of less than 150 nm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2021
From: MACLACHLAN, IAN; JEFFS, LLOYD; PALMER, LORNE R.; GIESBRECHT, NOELLE
To: PROTIVA BIOTHERAPEUTICS, INC.
Reel/Frame 056347/0993 →
MERGER Recorded May 25, 2021
From: PROTIVA BIOTHERAPEUTICS INC.
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 056392/0622 →